Guangzhou Wondfo Biotech Co.,Ltd
SZSE:300482.SZ
24.61 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,064.809 | 2,764.914 | 5,680.513 | 3,361.043 | 2,810.841 | 2,072.321 | 1,650.059 | 1,145.484 | 547.353 | 428.78 | 365.396 | 247.643 | 227.354 | 183.422 |
| Cost of Revenue
| 1,098.88 | 1,040.389 | 2,736.626 | 1,396.076 | 870.75 | 721.012 | 643.764 | 444.442 | 172.456 | 142.48 | 128.351 | 104.507 | 111.813 | 92.616 |
| Gross Profit
| 1,965.929 | 1,724.525 | 2,943.887 | 1,964.967 | 1,940.091 | 1,351.309 | 1,006.296 | 701.043 | 374.897 | 286.3 | 237.045 | 143.136 | 115.54 | 90.807 |
| Gross Profit Ratio
| 0.641 | 0.624 | 0.518 | 0.585 | 0.69 | 0.652 | 0.61 | 0.612 | 0.685 | 0.668 | 0.649 | 0.578 | 0.508 | 0.495 |
| Reseach & Development Expenses
| 411.516 | 378.001 | 418.836 | 391.095 | 279.426 | 160.444 | 137.231 | 35.027 | 18.461 | 15.128 | 11.353 | 12.673 | 13.96 | 0 |
| General & Administrative Expenses
| 72.23 | 87.372 | 79.832 | 117.92 | 67.986 | 64.306 | 66.885 | 55.979 | 25.517 | 15.027 | 16.781 | 13.842 | 11.639 | 38.645 |
| Selling & Marketing Expenses
| 254.748 | 649.988 | 929.611 | 644.306 | 631.127 | 497.514 | 358.341 | 237.938 | 134.402 | 96.513 | 83.844 | 47.576 | 32.677 | 25.64 |
| SG&A
| 326.978 | 737.359 | 1,009.443 | 762.226 | 699.112 | 561.82 | 425.226 | 293.917 | 159.919 | 111.541 | 100.625 | 61.418 | 44.316 | 64.285 |
| Other Expenses
| 590.59 | 60.026 | 100.885 | 82.261 | 92.324 | 71.695 | -2.851 | 6.112 | 15.782 | 22.545 | 23.305 | 25.68 | 12.56 | 13.375 |
| Operating Expenses
| 1,329.084 | 1,175.387 | 1,529.164 | 1,235.582 | 1,070.863 | 793.959 | 615.74 | 413.704 | 238.712 | 171.872 | 146.06 | 97.272 | 78.351 | 65.164 |
| Operating Income
| 636.845 | 549.138 | 1,367.732 | 691.897 | 740.092 | 508.781 | 411.993 | 260.602 | 158.723 | 121.791 | 91.491 | 44.024 | 29.866 | 23.076 |
| Operating Income Ratio
| 0.208 | 0.199 | 0.241 | 0.206 | 0.263 | 0.246 | 0.25 | 0.228 | 0.29 | 0.284 | 0.25 | 0.178 | 0.131 | 0.126 |
| Total Other Income Expenses Net
| -7.383 | -8.375 | -3.206 | -11.409 | -9.158 | -5.667 | -2.851 | 6.024 | 15.507 | 22.357 | 23.071 | 25.68 | 12.56 | 13.357 |
| Income Before Tax
| 629.463 | 540.763 | 1,364.526 | 680.489 | 730.934 | 503.114 | 409.142 | 266.714 | 174.23 | 144.148 | 114.562 | 69.704 | 42.426 | 36.433 |
| Income Before Tax Ratio
| 0.205 | 0.196 | 0.24 | 0.202 | 0.26 | 0.243 | 0.248 | 0.233 | 0.318 | 0.336 | 0.314 | 0.281 | 0.187 | 0.199 |
| Income Tax Expense
| 64.247 | 53.334 | 174.501 | 47.908 | 114.127 | 76.017 | 62.557 | 41.646 | 28.723 | 18.797 | 16.198 | 10.701 | 4.547 | 4.759 |
| Net Income
| 561.629 | 487.625 | 1,197.063 | 634.433 | 634.17 | 387.461 | 307.744 | 210.695 | 144.987 | 125.352 | 98.364 | 59.004 | 37.909 | 31.672 |
| Net Income Ratio
| 0.183 | 0.176 | 0.211 | 0.189 | 0.226 | 0.187 | 0.187 | 0.184 | 0.265 | 0.292 | 0.269 | 0.238 | 0.167 | 0.173 |
| EPS
| 1.21 | 1.1 | 2.71 | 1.43 | 1.44 | 0.88 | 0.71 | 0.52 | 0.35 | 0.35 | 0.32 | 0.19 | 0.12 | 0.17 |
| EPS Diluted
| 1.21 | 1.1 | 2.71 | 1.43 | 1.44 | 0.88 | 0.71 | 0.51 | 0.35 | 0.35 | 0.32 | 0.19 | 0.12 | 0.17 |
| EBITDA
| 932.242 | 859.13 | 1,673.502 | 921.219 | 890.71 | 621.005 | 485.759 | 320.524 | 198.296 | 135.615 | 132.343 | 84.936 | 54.882 | 25.642 |
| EBITDA Ratio
| 0.304 | 0.311 | 0.295 | 0.274 | 0.317 | 0.3 | 0.294 | 0.28 | 0.362 | 0.316 | 0.362 | 0.343 | 0.241 | 0.14 |